News Filgotinib Reduces Flare Risk in Uveitis in Phase 2 Study by Medscape • 2022/09/13 • 0 Comments Phase 2 data on filgotinib show a reduction in risk of flare in patients with uveitis and good tolerance in one of the first studies of a JAK inhibitor in uveitis. MDedge News Full Story →